Insulet Co. (NASDAQ:PODD) Shares Acquired by WoodTrust Financial Corp

WoodTrust Financial Corp increased its holdings in Insulet Co. (NASDAQ:PODD) by 57.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,365 shares of the medical instruments supplier’s stock after buying an additional 865 shares during the period. WoodTrust Financial Corp’s holdings in Insulet were worth $551,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norden Group LLC grew its position in shares of Insulet by 52.4% in the first quarter. Norden Group LLC now owns 2,718 shares of the medical instruments supplier’s stock valued at $466,000 after purchasing an additional 934 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Insulet by 34.4% during the first quarter. Janney Montgomery Scott LLC now owns 10,060 shares of the medical instruments supplier’s stock worth $1,724,000 after buying an additional 2,573 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Insulet by 5.4% in the first quarter. Nordea Investment Management AB now owns 5,362 shares of the medical instruments supplier’s stock worth $914,000 after acquiring an additional 274 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Insulet by 60.4% in the first quarter. Daiwa Securities Group Inc. now owns 10,477 shares of the medical instruments supplier’s stock valued at $1,796,000 after acquiring an additional 3,946 shares in the last quarter. Finally, Central Pacific Bank Trust Division purchased a new stake in shares of Insulet in the first quarter valued at $69,000.

Insulet Trading Down 0.8 %

PODD opened at $239.30 on Thursday. The firm’s 50 day moving average is $229.90 and its 200-day moving average is $202.95. Insulet Co. has a 52-week low of $151.56 and a 52-week high of $248.55. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $16.78 billion, a P/E ratio of 43.51, a P/E/G ratio of 4.43 and a beta of 1.22.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.38 EPS. Analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the topic of several analyst reports. Citigroup raised their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. BTIG Research raised their target price on shares of Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Barclays boosted their price target on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. UBS Group raised their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group upped their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $246.13.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.